UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2018
Creative Medical Technology Holdings, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 000-53500 | 87-0622284 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 2017 W Peoria Avenue, Phoenix, AZ 85029 |
| (Address of principal executive offices) |
Registrant’s telephone number, including area code: (833) 336-7636
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events |
On June 19, 2018, Creative Medical Technology Holdings, Inc., a Nevada corporation (the “ Company ”), issued a press release announcing the formation of CaverStem International LLC, a majority-owned subsidiary of the Company focused on commercializing stem cell therapy for erectile dysfunction to international physicians and their patients.
The press release, furnished as Exhibit 99.1 to this Form 8-K, may contain forward-looking statements. Such forward-looking statements are based on information presently available to the Company’s management and are current only as of the date made. Actual results could also differ materially from those anticipated as a result of a number of factors, including, but not limited to, those discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, and subsequent reports filed by the Company with the Securities and Exchange Commission (the “ Commission ”). For those reasons, undue reliance should not be placed on any forward-looking statement. The Company assumes no duty or obligation to update or revise any forward-looking statement, although it may do so from time to time as management believes is warranted or as may be required by applicable securities law. Any such updates or revisions may be made by the registrant by filing reports with the Commission, through the issuance of press releases or by other methods of public disclosure.
| Item 9.01. | Financial Statements and Exhibits |
| (d) | Exhibits. |
| Exhibit No. | Description | |
| 99.1 | Press Release dated June 19, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Creative Medical Technology Holdings, Inc. | ||
| Date: June 21, 2018 | By: | /s/ Timothy Warbington |
| Timothy Warbington, Chief Executive Officer | ||
Exhibit 99.1
Creative Medical Technology Holdings Forms CaverStem International LLC
Subsidiary to concentrate on International Erectile Dysfunction Market
PHOENIX and LOS ANGELES, June 19, 2018 /PRNewswire/ – Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of CaverStem International LLC, a majority owned subsidiary focused on commercializing stem cell therapy for erectile dysfunction to international physicians and their patients.
“Due to the enthusiastic response from international attendees at the American Urological Association conference held in May 2018, we’ve determined it is in the best interest of the company to form a subsidiary to pursue commercialization with physicians from around the world,” said Timothy Warbington President and CEO of Creative Medical Technologies, Inc. and Managing Member of CaverStem International LLC.
Dr. Alexander Gershman, an internationally renowned urologist, lecturer, inventor and Scientific Advisory Board Member at Creative Medical Technology Holdings, Inc., will take on an expanded role with CaverStem International, utilizing not only his vast expertise but also his international relationships in the urology community to expand our physician base. Dr. Gershman is one of the Managers and Members of this subsidiary. “We’re excited that Dr. Gershman who was the first physician to treat patients commercially with the CaverStem TM procedure, is taking on this role with the company,” Timothy Warbington said further.
“I am pleased to take on this expanded role as a Manager and Member of CaverStem International. As a treating physician I have experienced first hand the safety and efficacy of the CaverStem TM procedure and I’m excited to introduce our technology to my peers in the international urology community. Since beginning to offer the CaverStem™ procedure in December 2017 I have treated multiple patients of which approximately 90% have reported positive improvements. These are all patients for which pharmacological interventions such as Viagra and Cialis do not work,” said Dr. Alexander Gershman.
Creative Medical Health Technology Holdings is offering the Caverstem™ technology to selected physicians in the USA, which qualify according to the Company’s criteria. Approximately 30% of the 30,000,000 patients suffering from erectile dysfunction do not respond to drugs like Viagra, Cialis and Levitra, in part due to an underlying degeneration of the biological machinery needed to achieve erections.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com . For more information on the procedure go to www.caverstem.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.